Morgan Stanley Initiates Myriad Genetics With Underperform

Loading...
Loading...
Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics
MYGN
with a Underperform rating. The target price for Myriad Genetics is set to $25. Myriad Genetics shares have gained 29.61% over the past 52 weeks, while the S&P 500 index has surged 14.68% in the same period. Myriad Genetics' shares fell 1.98% to $34.20 in pre-market trading.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...